Longeveron (LGVN) Shares Surge On $30 Million Private Placement Deal

Longeveron Inc (NASDAQ:LGVN) shares are trading sharply higher on Tuesday afternoon following the announcement of a private placement agreement worth up to $30 million. Here’s what investors need to know.

• Longeveron stock is charging ahead with explosive momentum. What’s fueling LGVN momentum?

Longeveron Raises $15M To Advance Laromestrocel Therapy

The clinical-stage biotech company, which specializes in cellular therapies for rare pediatric and aging-related conditions, secured the funding to advance its lead candidate, laromestrocel.

The financing is structured in two tranches. The initial closing, expected around Wednesday, will provide $15 million in gross proceeds. This tranche was led by Coastlands Capital with participation from Janus Henderson Investors and other health care funds.

Shares and convertible preferred stock were priced at 52 cents per share, reflecting an at-the-market valuation under Nasdaq rules.

Cash Runway Extended Ahead Of Crucial HLHS Trial Data

Crucially, this capital extends Longeveron's cash runway into the fourth quarter of 2026. This ensures the company remains funded through the high-stakes Phase 2b ELPIS II trial data readout for Hypoplastic Left Heart Syndrome (HLHS), anticipated in third-quarter 2026. A second $15 million tranche is available upon achieving specific clinical milestones and stock price targets.

As part of the deal, investors are entitled to 50% of the proceeds from any future sale of a Rare Pediatric Disease Priority Review Voucher, should the FDA grant one for the HLHS program.

Analysts at Zacks Small-Cap Research currently maintain a valuation of $10.45 on the stock, citing the “game-changing potential” of its regenerative pipeline.

LGVN Stock Surges Tuesday Afternoon

LGVN Price Action: Longeveron shares were up 74.32% at 92 cents at the time of publication on Tuesday.

Image: Shutterstock

This article Longeveron (LGVN) Shares Surge On $30 Million Private Placement Deal originally appeared on Benzinga.com